CTOR (STOCKS)

    Citius Oncology, Inc. Common Stock

    $1.060000
    -0.070000 (-6.19%)
    Prev close: $1.130000
    Company Information
    Exchange
    XNAS
    Sector
    Health Technology
    Industry
    Pharmaceuticals: Major
    CEO
    Leonard L. Mazur
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    $100.63M
    Employees
    P/E (TTM)
    -3.34
    P/B (TTM)
    2.10
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Sep 2025)
    Revenues $0.00
    Nonoperating Income/Loss -$181.66K
    Operating Expenses $23.52M
    Research and Development $6.42M
    Other Operating Expenses $17.10M
    Operating Income/Loss -$23.52M
    Income/Loss From Continuing Operations After Tax -$24.76M
    Income/Loss From Continuing Operations Before Tax -$23.70M
    Income Tax Expense/Benefit $1.06M
    Income Tax Expense/Benefit, Deferred $1.06M
    Interest Expense, Operating $218.03K
    Net Income/Loss -$24.76M
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent -$24.76M
    Net Income/Loss Available To Common Stockholders, Basic -$24.76M
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share -$0.34
    Diluted Earnings Per Share -$0.34
    Basic Average Shares 73,267,969
    Diluted Average Shares 73,267,969
    Assets $100.94M
    Current Assets $27.54M
    Inventory $22.29M
    Prepaid Expenses $1.33M
    Other Current Assets $3.92M
    Noncurrent Assets $73.40M
    Liabilities $56.08M
    Current Liabilities $49.49M
    Accounts Payable $13.23M
    Other Current Liabilities $36.26M
    Noncurrent Liabilities $6.59M
    Equity $44.87M
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $44.87M
    Liabilities And Equity $100.94M
    Net Cash Flow From Operating Activities -$5.49M
    Net Cash Flow From Operating Activities, Continuing -$5.49M
    Net Cash Flow From Investing Activities -$5.75M
    Net Cash Flow From Investing Activities, Continuing -$5.75M
    Net Cash Flow From Financing Activities $15.17M
    Net Cash Flow From Financing Activities, Continuing $15.17M
    Net Cash Flow $3.92M
    Net Cash Flow, Continuing $3.92M
    Comprehensive Income/Loss -$24.76M
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent -$24.76M
    Other Comprehensive Income/Loss $0.00